FOLH1 and posterior cortical atrophy: The NEPI trial is a single-center (Germany) randomized phase I/II study (not yet recruiting) that aims to explore neoadjuvant [177Lu]Lu-PSMA-617 with or without Ipilimumab in 58 high-risk PCa candidates for RPE (tissue specimen must be available), at maximum oligometastatic on PSMA PET with prostatic SUVmax > 12 (M1 patients at CI will be excluded).